BRCA1

Yemaachi Presents Findings on Mutation Profiles of Ghanaian Women with Breast Cancer at AORTIC 2023; Announces Formation of African Clinical Cancer Research Network

Retrieved on: 
星期一, 十一月 6, 2023
Research, Professional Services, Data Management, Oncology, Consumer, Technology, Genetics, Health Technology, Data Analytics, Science, Biotechnology, Women, Health, VAF, System, Therapy, TP53, BRCA1, PIK3CA, Conference, NF1, University, BRCA2, Sequence, Breast cancer, Hospital, Cell biology, Woman, Patient, Vision, African, Pharmaceutical industry, Cancer

The study profiled 106 samples of Ghanaian women with breast cancer with whole exome sequencing to identify associated somatic and driver mutations.

Key Points: 
  • The study profiled 106 samples of Ghanaian women with breast cancer with whole exome sequencing to identify associated somatic and driver mutations.
  • The network will be focused on promoting pan-African cancer research, led by African clinicians and scientists and performed on the continent.
  • Yemaachi already has an extensive network of 24 academic institutions, corporate partners, and hospitals across nine African countries who will be founding network members.
  • To learn more about participating in the AfriCAN network, potential members can get in touch at [email protected] .

AI-Powered Tumor Microenvironment Analysis Predicts Treatment Outcomes in NSCLC Patients with EGFR Mutation: Groundbreaking Studies to be Presented by Lunit at SITC 2023

Retrieved on: 
星期三, 十一月 1, 2023
TKI, TILS, Patient, Neoplasm, The Cancer Genome Atlas, TCGA, NSCLC, PTEN, Progression-free survival, Biomarker, Therapy, Booth, ICI, BRCA1, Data, PFS, PIK3CA, Phenotype, Inflammation, TIL, Samsung Medical Center, BRCA2, OR, TNBC, IL1A, SITC, Immunotherapy, Methylation, ITIL, Annual general meeting, Breast cancer, Triple-negative breast cancer, Gene, Tumor microenvironment, Lung cancer, Society, IL17A, Cancer, TFI, TME, STIL, Mutation, EGFR, Medical imaging

The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes.

Key Points: 
  • The study found that EGFR-TKI affects the immune landscape of EGFR-mutated NSCLC as higher PD-L1 expression and differential immune phenotypes.
  • Patients with an inflamed immune phenotype after EGFR-TKI treatment showed a more favorable response to subsequent immune checkpoint inhibitors (ICI) treatment.
  • Another study investigated the effect of tumor fragmentation index (TFI), the number of tumor fragments per total tumor area, in TME.
  • Visit Lunit's booth at SITC 2023 at Booth #227 to learn more about these pioneering studies.

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
星期一, 十月 23, 2023
Colon, Oncolytics Biotech, Genetics, News, Lung, Disease, Risk, Messenger, Lijun International Pharmaceutical (Holding) Co. Ltd., BNTX, Glycine, BioNTech, G12, Hope, RET, Prostate cancer, BRCA2, Cancer, Immune system, Pancreatic cancer, ORR, Hand, University, Roche, Therapy, Patient, Natural history of disease, DNA, CR, Eli Lilly and Company, CAD, 23andMe, JD, OTC, Eli Lilly, FOLFIRINOX, BRCA, Research, Clinical trial, BBB National Programs, Survival rate, Aspartic acid, Valine, Woman, ONC, MD Anderson Cancer Center, TSX, PCCP, Survival, FDA, Lilly, Attention, AACR, Incidence, BRCA1, New View (Eleanor Friedberger album), MBA, KRAS, Entrepreneurship, Breast, Diagnosis, Prostate, FTD, Pharmaceutical industry, Medical imaging, Vaccine, Nature

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

Retrieved on: 
星期一, 十月 23, 2023
Colon, Oncolytics Biotech, Genetics, News, Lung, Disease, Risk, Messenger, Lijun International Pharmaceutical (Holding) Co. Ltd., BNTX, Glycine, BioNTech, G12, Hope, RET, Prostate cancer, BRCA2, Cancer, Immune system, Pancreatic cancer, ORR, Hand, University, Roche, Therapy, Patient, Natural history of disease, DNA, CR, Eli Lilly and Company, CAD, 23andMe, JD, OTC, Eli Lilly, FOLFIRINOX, BRCA, Research, Clinical trial, BBB National Programs, Survival rate, Aspartic acid, Valine, Woman, ONC, MD Anderson Cancer Center, TSX, PCCP, Survival, FDA, Lilly, Attention, AACR, Incidence, BRCA1, New View (Eleanor Friedberger album), MBA, KRAS, Entrepreneurship, Breast, Diagnosis, Prostate, FTD, Pharmaceutical industry, Medical imaging, Vaccine, Nature

VANCOUVER, BC, Oct. 23, 2023 /PRNewswire/ -- USA News Group - Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the oncology field, the third leading cause of cancer death in the USA. Still not fully understood, pancreatic cancer's 5-year survival rate is currently only 12%. New analysis of data from the National Program of Cancer Registries database, covering around 65% of the US population, suggests that the incidence of pancreatic cancer among individuals younger than 55 years is increasing more rapidly than in those 55 years or older, and also more quickly in women than in men. As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder. Thankfully, within the biotech sector, there have been plenty of developments giving hope in the fight against pancreatic cancer, including those from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Eli Lilly and Company, Roche Holding AG (OTC:RHHBY), BioNTech SE (NASDAQ:BNTX), and even 23andMe Holding Co (NASDAQ:ME).

Key Points: 
  • As more and more cases of young people are showing up, calls from the leading pancreatic cancer organization PanCAN to increase funding for research are getting louder .
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • The BRCA1 and BRCA2 variants may also be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers.
  • "It's an important milestone that shows we're headed in the right direction – and this means so much to all those affected by pancreatic cancer."

PreCheck Health Genetic Testing: A Vital Tool in the Battle Against Hereditary Cancers

Retrieved on: 
星期四, 十月 12, 2023
Health, Knowledge, Cancer, Physician, Hope, Breast cancer, Breast, BRCA2, Risk, Heredity, Genetic, Genetic testing, Genetics, Mutation, BRCA1, Role, Ovarian cancer, Weakness, Fatigue, USPSTF, BRCA, Dizziness, Patient, Colon, Colorectal cancer, Uncertainty, Ovary, Vaccine, Birth control, Mobile phone, Dietary supplement, Nursing

PreCheck Health, we'll delve into the significance of genetic testing in identifying hereditary cancer risks and its role in promoting early screening.

Key Points: 
  • PreCheck Health, we'll delve into the significance of genetic testing in identifying hereditary cancer risks and its role in promoting early screening.
  • Learn why genetic testing is crucial for patients with a strong family history of breast, colon, and ovarian cancers.
  • But what exactly makes these cancers so hereditary, and how can genetic testing help in early detection and prevention?
  • The Role of Genetic Factors: In hereditary cancers, specific gene mutations are passed down from one generation to the next.

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

Retrieved on: 
星期四, 八月 31, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., Pancreatic cancer, 23andMe, PCCP, DNA, Disease, Sanger, Ashkenazi Jews, Genetics, BRCA1, Food and Drug Administration, Cancer, Breast, Prostate, PGS, Marketing, Risk, Artificiality, Genetic testing, Entrepreneurship, BRCA2, BRCA, Health, FDA, Ovarian cancer, Gene, African Americans, Food, Saliva, Breast cancer, Prostate cancer, Birth control, Medical device, Pharmaceutical industry, Dietary supplement

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced the Company has received a U.S. Food and Drug Administration (FDA) 510(k) clearance to expand its existing BRCA1/BRCA2 (Selected Variants) Genetic Health Risk Report*. The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer. 23andMe received the first FDA authorization for a direct-to-consumer genetic test for cancer risk in 2018 to report 3 variants in the BRCA1 and BRCA2 genes, primarily found in people of Ashkenazi Jewish descent. Many of the 41 BRCA variants added through this clearance are known to have a higher rate of occurrence in populations traditionally underserved by genetic testing, including the African American and Hispanic/Latino communities. This marks the Company’s fourth FDA clearance for genetic cancer risk.

Key Points: 
  • The clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer.
  • In addition to the 510(k) clearance, the FDA also granted 23andMe the first-ever Predetermined Change Control Plan (PCCP), which allows the Company to add additional validated BRCA1 and BRCA2 variants and associated cancer risk information to its BRCA1/BRCA2 (Selected Variants) report without additional premarket review.
  • 23andMe also underwent robust analytical validation in order to meet FDA requirements to add variants to the BRCA1/BRCA2 (Selected Variants) report.
  • This clearance is the eighth pre-market authorization granted by the FDA to 23andMe covering its multiplexed Personal Genome Service.

Prostate Conditions Education Council Hosts a Prostate Cancer & Sexual Health + Intimacy Education Event in Memphis

Retrieved on: 
星期四, 八月 31, 2023
Knowledge, Learning, Prostate cancer, Education, RISK, Friends, DRE, Average, BRCA1, Hereditary nonpolyposis colorectal cancer, Cancer, Quality of life, Veteran, First responder, American Cancer Society, Google Images, POWER, Ukrainian American Educational Council, American Men and Women of Science, PCA, Genealogy, Patient, Risk, Father, Diagnosis, FDA, PSA, Disease, Birth control, Medical imaging, Dairy, Dietary supplement, Breast, BRCA2

MEMPHIS, Tenn., Aug. 31, 2023 /PRNewswire/ -- The Prostate Conditions Education Council (PCEC) is proud to announce its upcoming event focused on Prostate Cancer & Sexual Health + Intimacy Education, to be held on Thursday, September 28th, 2023, at 5:00 pm.

Key Points: 
  • MEMPHIS, Tenn., Aug. 31, 2023 /PRNewswire/ -- The Prostate Conditions Education Council (PCEC) is proud to announce its upcoming event focused on Prostate Cancer & Sexual Health + Intimacy Education, to be held on Thursday, September 28th, 2023, at 5:00 pm.
  • Prostate cancer is a critical health concern for many individuals, and the goal of this event is to provide education and support to those affected by the condition.
  • The event will cover a range of topics related to prostate cancer, sexual health, and intimacy, offering valuable insights and information for both patients and their loved ones.
  • In addition to addressing medical aspects, the event will also include a special presentation on sexual health and intimacy after prostate cancer, a crucial and often sensitive aspect of the cancer journey.

DNA Repair Discoveries Hold Promise for New Approaches to Cancer Treatment

Retrieved on: 
星期三, 八月 16, 2023
Memorial Sloan Kettering Cancer Center, DNA, Radiation, WCM, Nature, DNA repair, NYU Langone Health, BRCA1, Microscopy, Cancer, MSKCC, Breast, Mutation, Cell, Doctor of Philosophy, Whole genome sequencing, National Cancer Institute, Protein, Chromosome, MD, Patient, WGS, Weill Cornell Medicine, Biology, Anurag Agrawal (medical scientist), BRCA2, BRCA, NCI, Homologous recombination, Vaccine, Microscope

In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.

Key Points: 
  • In cells that cannot repair DNA effectively, changes (mutations) can occur that lead to cancer.
  • Most cells rely on a system called homologous recombination or HR, which uses proteins called BRCA1 and BRCA2 for accurate DNA repair.
  • For this reason, identifying patients with "HR-deficient" cancers has become a priority in the field, in part because such cancer cells are vulnerable to targeted therapies that break their DNA.
  • This work was supported by the Starr Cancer Consortium Award I11-005, National Cancer Institute (NCI) 1P50CA247749, and the Burroughs Wellcome Fund Career Award for Medical Scientists.

United States DTC Wellness Testing Markets, Competition, Opportunity, and Forecast, 2018-2023 & 2023-2028F - ResearchAndMarkets.com

Retrieved on: 
星期五, 八月 4, 2023
General Health, Genetics, Health, EUA, Insurance, DTC, DNA, Quest Diagnostics, Partnership, Mouth, Prevalence, HIV, Fetus, BRCA1, COVID-19, Cancer, Genetic testing, Labcorp, Infection, Privacy, Hepatitis C, Competition, Market, Internet, Chromosome, Collection, Patient, Risk, Physician, Growth, BRCA2, State, Roger Hawkins (drummer), Gene, Syphilis, Saliva, Breast cancer, Disease, Retail, Security (finance), Vaccine, Pharmaceutical industry, Nordstrom

The United States DTC Wellness Testing Market is expected to grow with an impressive CAGR in the forecast period 2024-2028.

Key Points: 
  • The United States DTC Wellness Testing Market is expected to grow with an impressive CAGR in the forecast period 2024-2028.
  • United States DTC Wellness Testing Market is growing on account of growing awareness among the population regarding DTC Wellness Testing, along with its benefits and consumer convenience related with it.
  • The growing awareness about wellness testing is creating a huge demand for the DTC Wellness testing market among the population in case of rising demand for DTC wellness Testing offerings such as home health & wellness kits.
  • Company Profiles: Detailed analysis of the major companies present in United States DTC Wellness Testing Market.

St. Luke's University Health Network and Helix Partner on Population Genomics Research Program to Accelerate Precision Medicine

Retrieved on: 
星期二, 六月 27, 2023
Sequence, HealthPartners, DNA, Partnership, Senior, Life, BRCA1, WellSpan Health, Hereditary nonpolyposis colorectal cancer, Cardiovascular disease, Cancer, FH, Genetic testing, Medical school, Medicine, Research, Genomics, History, Privacy, Confidentiality, Participation, Hereditary breast–ovarian cancer syndrome, Medical University of South Carolina, Patient, Physician, Colorectal cancer, University Health Network, BRCA2, Ovarian cancer, ST, Disease, Hospital, Nursing, Birth control, St Luke's, Helix

"The St. Luke's-Helix partnership will create a unique research program in our region that will greatly expand those capabilities to benefit more patients.

Key Points: 
  • "The St. Luke's-Helix partnership will create a unique research program in our region that will greatly expand those capabilities to benefit more patients.
  • The St. Luke's-Helix community health research program initially aims to enroll 100,000 participants over four years.
  • "We're delighted to partner with St. Luke's and other leading health systems deploying genomics at scale across the United States."
  • Details regarding participation in the community health research program will be provided to potential participants later this year, prior to the official launch date.